UK Research and Innovation Launches £80m Dementia Challenge for NHS

UK Research and Innovation has launched an up-to-£80 million Dementia Challenge to test nine medical technologies within the NHS. The government-backed initiative aims to accelerate the adoption of faster diagnostics and home monitoring tools, pushing the proportion of patients diagnosed within 18 weeks of referral to 92 per cent.

Dementia causes more deaths in the United Kingdom than any other disease, accounting for almost one in eight deaths according to data cited by Alzheimer’s Research UK. With over 72,000 people dying from dementia and Alzheimer’s disease across the UK in 2025, patients and their families frequently face waiting lists lasting months, and in some cases more than a year, to receive a formal assessment.

To address those delays, the UK government through UK Research and Innovation is deploying funding via the Research and Development Missions Accelerator Programme. The programme targets a substantial operational shift for the National Health Service: raising the current diagnostic rate of around 60 per cent of referred patients within 18 weeks up to a national goal of 92 per cent.

Nine Innovative Projects Selected for Real-World NHS Evaluation

The initiative moves away from traditional, unconditional long-term grants by adopting a fail-fast funding model. Projects chosen for the challenge must hit specific milestones and demonstrate measurable patient benefits to secure ongoing financial support, ensuring that only effective innovations scale across clinical settings.

RADIANCE MRI Protocol: University College London and the UK Dementia Research Institute are evaluating an artificial-intelligence-powered MRI protocol designed to reduce brain scan times from roughly 20 minutes down to seven minutes.
Blood Biomarker Integration: Researchers from the University of Oxford, University of Cambridge, Imperial College London, and Dementias Platform UK are introducing blood-based biomarkers validated through the READ-OUT study into six to ten NHS memory service sites.
PROTECT Cognitive Health Tool: The University of Exeter is integrating a digital platform into the NHS allowing people to monitor cognitive changes from home and help triage waiting lists.
DIADEM Hearing Assessment: Queen Mary University of London and UCL are testing four short computer-based listening tests that assess how the brain processes sound, as hearing difficulties can emerge early in certain forms of dementia.
AI Clinical Decision Support: The University of Cambridge is developing an AI-enabled tool that analyzes routine medical records, blood tests, and cognitive assessments to predict disease progression.
Scottish Service Redesign: The University of Edinburgh and NHS Research Scotland are redesigning dementia services across Scotland and establishing living labs to test novel biomarkers and treatments.

Research Leadership and Institutional Reactions to the Dementia Challenge

Professor Vanessa Raymont, Director of DPUK and Director of Research and Development at Oxford Health NHS Foundation Trust, highlighted the clinical potential of incorporating blood tests into routine care.

UK Research and Innovation Launches £80m Dementia Challenge for NHS — Photo: Webwire

“Blood-based biomarkers have the potential to transform dementia diagnosis within NHS memory services. Building on the evidence generated through the READ-OUT study, this project will help us understand how these tests can be integrated into routine clinical pathways and at which point they would be most effective in supporting timely and accurate diagnoses.”

Professor Vanessa Raymont, Director of DPUK and Director of R&D at Oxford Health NHS Foundation Trust

The University of Exeter noted that long diagnostic waits exacerbate poor mental health and well-being. The team’s home-monitoring technology aims to triage the thousands of people waiting for a diagnosis and ensure the right patients enter clinics at the correct time.

UKRI health mission challenge director Andy Hill emphasized the dual objective of the funding initiative.

Calls for a National 18-Week Target and Remaining Service Challenges

Charities monitoring the rollout point out that roughly one in three people living with dementia in the UK currently lack a diagnosis, preventing them from accessing timely treatments, care support, and research opportunities. Dr Richard Oakley, Associate Director of Research and Innovation at the Alzheimer’s Society, said the initiative could transform NHS memory services.

“This work by brilliant UK researchers could be transformative in getting people the early treatment they need, improving the quality of life for people across our country.”

Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society

The evaluation projects will generate real-world evidence over the coming years, with teams aiming to establish standardized clinical blueprints across NHS sites by 2029.